Patents
Literature
60 results about "Multiglycosidorum tripterygii" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Multiglycosidorum tripterygii, a new immunosuppressant, supresses coronary arteriosclerosis after heart transplantation. Hachida M(1), Zhang X, Lu H, Hoshi H, Koyanagi H. Author information: (1)Department of Cardiovascular Surgery, The Heart Institute of Japan, Tokyo Women's Medical College.
Tripterygium glycoside-containing micro-emulsified gel transdermal preparation and preparation method thereof
InactiveCN102462723ASimple manufacturing processImprove product qualityAntipyreticAnalgesicsActive agentSurface-active agents
The invention belongs to the technical field of medicinal preparations and relates to a tripterygium glycoside-containing micro-emulsified gel transdermal preparation and a preparation method thereof. The preparation method is characterized in that a gel matrix is added into microemulsion and the mixture is further processed into the tripterygium glycoside-containing micro-emulsified gel transdermal preparation. The tripterygium glycoside-containing micro-emulsified gel transdermal preparation comprises: by mass, 0.1 to 15% of tripterygium glycoside, 15 to 20% of one or more surfactants, 30 to 40% of one or more auxiliary surfactants, 15 to 25% of oil phases, 15 to 25% of water, 0.5 to 2% of one or more transdermal absorption promoters, and 0.5 to 5% of one or more gel base materials. Thetripterygium glycoside-containing micro-emulsified gel transdermal preparation is semitransparent or transparent, has nattier blue opalescence and a pH value of 6 to 10 and can form micro-emulsion having particle sizes of 10 to 100nm, can be processed into pasters so that drug transdermal delivery is realized, has low skin irritation, can be prepared by the simple preparation method, and has stable quality and good drug transdermal absorption promotion performances.
Owner:FUDAN UNIV
Tripterygium glycosides nano-emulsion gel and preparation method thereof
ActiveCN107303263AAppropriate viscosityBroaden applicationOrganic active ingredientsAntipyreticAdditive ingredientGlycoside formation
The invention belongs to the technical field of a pharmaceutical preparation and specifically relates to a tripterygium glycosides nano-emulsion gel, a preparation method thereof and an application thereof. The main ingredients of the tripterygium glycosides nano-emulsion gel disclosed by the invention include raw material tripterygium glycosides, an oil phase, a surfactant, a cosurfactant, a gel matrix and deionized water. The method comprises the following steps: mixing tripterygium glycosides with the oil phase, surfactant and cosurfactant; dropwise adding the deionized water into the mixed solution; magnetically stirring, thereby acquiring the tripterygium glycosides nano-emulsion; and adding the gel matrix, thereby acquiring the tripterygium glycosides nano-emulsion gel. The invention selects an O / W type nano-emulsion as a transdermal drug delivery carrier for preparing a tripterygium glycosides nano-emulsion gel transdermal preparation and provides a novel effective drug preparation for the clinical application of tripterygium glycosides.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Compound Tripterygium wilfordii multi-glycosides formulation for curing rheumatic disease and preparation method thereof
InactiveCN101297841AImprove joint damageReduce congestion and edemaOrganic active ingredientsAntipyreticDiseaseTreatment effect
The invention relates to a compound tripterygium glycoside preparation for treatment for rheumatic diseases and a preparation method thereof. The invention takes tripterygium glycoside and artemether as main drugs and is in combination with pharmaceutical excipients, microcrystalline cellulose, lactose, low-substituted hydroxyproxyl cellulose, tiny powder silica gel and magnesium stearate for preparing tablets. The weight ratio is that: 5g of tripterygium glycoside and 5 to 30g of artemether. The invention proposes to allow the tripterygium glycoside and the artemether to be compatible to realize the synergy of the efficacies, and the compatibility of the tripterygium glycoside and the artemether has higher treatment effects on rheumatic diseases than that of the tripterygium glycoside.
Owner:JIANGXI HERBFINE HI TECH
Method for extracting tripchlorolide from tripterygium wilfordii front segment
The invention discloses a method for extracting tripchlorolide from tripterygium wilfordii front segment extractum. At present, tripchlorolide with little amount is obtained by employing a multi-time chromatography method to perform chromatographic separation on tripterygium glycosides or an extraction product directly extracted from tripterygium wilfordii raw material by ethanol and perform rotating thin layer chromatography, and the method cannot be used to large-scale production at all. The method provided by the invention comprises: utilizing a hydrophilic solvent low alcohol / ketone to perform extraction on the tripterygium wilfordii front segment extractum, separating majority of lipophilic impurities in the front-segment extractum, then extracting with trichloromethane to separate some other non-target products with relatively small solubility in the low alcohol / ketone, then performing chromatographic separation purification, and finally utilizing chloroform to perform recrystallization. The method provided by the invention is simple and practicable in separation and purification technology, is suitable for industrialized large-scale production; and the prepared tripchlorolide is applicable to develop new drugs.
Owner:浙江得恩德制药股份有限公司
Method for reducing organic solvent residue in tripterygium glycoside
The invention relates to a method for reducing an organic solvent residue in tripterygium glycoside. Organic solvents (mainly comprising ethanol and chloroform) are adopted to carry out collection, extraction, chromatography and the like in a production technology of the tripterygium glycoside, and the problem of an unstable index of the organic solvent residue in the tripterygium glycoside is generated at present. The method comprises the following steps: dissolving a tripterygium glycoside semi-finished product by absolute ethyl alcohol, and fully agitating to evenly dissolve; concentrating the obtained tripterygium glycoside ethanol solution, and pumping out at reduced pressure after recovering ethanol, so as to obtain a powdery dry product; and obtaining the tripterygium glycoside product by adopting a method of combining warm water precipitation with low-temperature vacuum drying. By adopting the method, the organic solvent residue in the tripterygium glycoside can be effectively reduced, and the quality is stable.
Owner:浙江得恩德制药股份有限公司
A kind of method for extracting tripterygium chloractone from tripterygium wilfordii extract
Owner:浙江得恩德制药股份有限公司
Leixihaokang, preparation method therefor, and use thereof
PCT designated stageWO2025166873A1Organic active ingredientsDermatological disorderApoptosisInflammatory infiltration
The present invention belongs to the field of traditional Chinese medicines, and particularly relates to Leixihaokang, a preparation method therefor, and use thereof. The Leixihaokang of the present invention is prepared from the following active pharmaceutical ingredients in parts by weight: 10 parts of Tripterygium glycosides and 0.1-1.3 parts of Artemisia annua extract. According to the present invention, animal experiments prove that the Leixihaokang can ameliorate renal damage in nephrotic syndrome caused by adriamycin, reduce the occurrence of proteinuria, and reduce the apoptosis of renal tissue cells. Meanwhile, the Leixihaokang of the present invention has a good inhibitory effect on renal, hepatic, splenic, and cardiac toxicity in the treatment process of nephrotic syndrome. According to the present invention, animal experiments also prove that the Leixihaokang can ameliorate skin injury in imiquimod-induced psoriasis, reduce inflammatory infiltration and alleviate skin damage. Meanwhile, the Leixihaokang has a certain degree of inhibitory effect on the hepatic and reproductive system toxicity in the treatment process of psoriasis.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE +2
Application of Wubi Shanyao pills to preparation of POI (premature ovarian insufficiency) treatment drug
InactiveCN111514222AIncrease the number ofImprove gripHeavy metal active ingredientsPill deliveryRehmanniae RadixMultiglycosidorum tripterygii
The invention discloses application of Wubi Shanyao pills to preparation of a POI (premature ovarian insufficiency) treatment drug. The Wubi Shanyao pills are prepared from rhizoma dioscoreae, herba cistanche, fructus schizandrae, semen cuscutae, cortex eucommiae, radix achyranthis bidentatae, rhizoma alismatis, radix rehmanniae praeparata, fructus corni, poria cocos, radix morindae officinalis and halloysitum rubrum. A female ICR mouse is subjected to intragastric administration by adopting tripterygium glycosides for 10 weeks to induce POI, molding is carried out, then the model mouse is continuously subjected to intragastric administration by adopting the Wubi Shanyao pills for 12 weeks, it is found that compared with a model control group, the Wubi Shanyao pill administration group hasthe advantages that the holding power of the model mouse can be obviously increased, the average estrous cycle days are shortened, the number of granular cell layers and the number of preantral follicles and sinus follicles are increased, the serum LH level is reduced, the Wubi Shanyao pills have a remarkable improvement effect on the POI mouse, so that the POI treatment or improvement effect isachieved, and good news is brought to the POI patient.
Owner:HANGZHOU HUQINGYUTANG PHARM CO LTD
Tripterygium wilfordii medicinal material and method for determining wilforlidea in tripterygium wilfordii polyglycosides tablet
ActiveCN110687224AReduce dosageHigh recovery rateComponent separationChromatographic separationLiquid liquid partition
The invention provides a tripterygium wilfordii medicinal material and a method for determining wilforlidea in a tripterygium wilfordii polyglycosides tablet. The method comprises the following stepsof taking an ethanol solution of 0.1 mg.mL<-1> of wilforlidea as a reference substance solution; acquiring a corresponding volume ratio range by establishing and optimizing normal hexane, ethyl acetate, ethanol and water of a solvent system so that a distribution coefficient K of the wilforlidea in the solvent system is 0.5-2; optimizing and controlling a rotating speed of a liquid-liquid distribution chromatographic separation column and a flowing speed of a mobile phase, and detecting the tripterygium wilfordii medicinal material and the method for determining the wilforlidea in the tripterygium wilfordii polyglycosides tablet by combining high performance liquid chromatography. The method is simple in operation process, high in specificity and good in reproducibility, separation cost isgreatly reduced, a wilforlidea chromatographic separation degree is high, a product recovery rate is high too, a sample dosage is small, stability is good, precision is high, qualitative and quantitative accuracy is high too, and quality of the tripterygium wilfordii medicinal material and the tripterygium wilfordii polyglycosides tablet can be effectively evaluated.
Owner:ZHEJIANG UNIV OF TECH
Application of tripterygium glycosides tablets in improving central sensitization pain
The invention relates to application of tripterygium glycosides tablets to improvement of central sensitization pain. The invention provides application of a tripterygium glycoside tablet in preparation of a product. The product is used for preventing or treating central sensitization pain. Based on animal experiment verification, the inventor of the invention finds that the tripterygium glycoside tablet can be used for treating the central sensitization type pain, and a new treatment means is provided for the central sensitization type pain.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Codonopsis pilosula polysaccharide gel containing tripterygium glycosides ethosome as well as preparation method and application of codonopsis pilosula polysaccharide gel
The invention discloses radix codonopsis polysaccharide gel containing tripterygium glycosides ethosome in the technical field of medicine and pharmacy. The radix codonopsis polysaccharide gel is prepared from tripterygium glycosides ethosome, a gel matrix, ultrapure water, a humectant, a thickening agent, a preservative and a hydrochloric acid solution. The ratio of the tripterygium glycosides ethosome to the gel matrix to the ultrapure water to the humectant to the thickening agent to the preservative is (0.5-2.5) ml: (150-1200) mg: (6-8) ml: (0.5-2) ml: (50-200) mg: (5-30) mg; the gel matrix is formed by cross-linking carboxymethylated chitosan and derivatized codonopsis pilosula polysaccharide, the mass ratio of the carboxymethylated chitosan to the derivatized codonopsis pilosula polysaccharide is (2: 1)-(4: 1), and the hydrochloric acid solution is used for adjusting the pH value of the codonopsis pilosula polysaccharide gel containing the tripterygium glycosides ethosome to be neutral. The radix codonopsis polysaccharide gel containing the tripterygium glycosides ethosome can be used as a medicine for resisting rheumatoid joints and other autoimmune diseases.
Owner:ZUNYI MEDICAL UNIVERSITY
Kunxinning and preparation method and application thereof
The invention belongs to the field of traditional Chinese medicine, and particularly relates to Kunxinning and a preparation method and application thereof. The effective components of the Kunxingning disclosed by the invention are artemisinin and artemisinin. Animal experiments prove that kunxingning can improve the early-onset ovarian insufficiency toxicity state of SD rats caused by tripterygium glycosides, reduce ovarian granular cell apoptosis, improve the ovarian pathological state, promote follicular development, restore the serum sex hormone level to be normal to a certain extent, improve the state of proportion imbalance of Th17 / Treg immune cells, and improve the early-onset ovarian insufficiency toxicity of the SD rats. And the mood cycle of the rats is recovered to a certain extent. Meanwhile, the physiological activity of the tripterygium glycosides composition obtained by compounding the kunxingning and the TG is equivalent to that of the TG.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE +1
A kind of tripterygium glycosides and tripterygium monomer synergistic and attenuated toxicity compatibility method
ActiveCN107468742BImprove IC50Reduce apoptosisHydroxy compound active ingredientsImmunological disordersSide effectLeukemia
The invention relates to the field of traditional Chinese medicine, and discloses a method for synergizing and attenuating toxicity of tripterygium glycosides and tripterygnee monomers, in which tripterygium polyglycosides or tripterygnee monomers are compatible with resveratrol as a medicine application. The technology of the present invention uses the tripterygium wilfordii main component tripterygium glycosides or tripterygium and resveratrol compatibility to play a synergistic and detoxifying effect. Resveratrol can increase the IC50 of tripteryne on intestinal epithelial cells, and reduce the IC50 of tripteryne on basophilic leukemia cells; it can reduce the apoptosis of intestinal epithelial cells induced by tripteryne; and further found that Veratrol-related effects work by activating Sirt protein. The invention can greatly expand the use of tripterygium wilfordii, tripterygium glycosides and tripterygium wilfordii, reduce the side effects of clinical medication, and reduce pain for clinical patients.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY
Method for determining dulcitine in blood plasma
The invention belongs to the technical field of biological detection and pharmaceutical analysis, and particularly relates to a method for determining dulcitine in blood plasma. The concentration of the dulcitine in the blood plasma is detected by adopting an ultra-high performance liquid chromatography-mass spectrometry method, a new guarantee means is provided for the medication safety of the tripterygium glycosides tablets, and meanwhile, a new method is provided for measuring the blood concentration of the dulcitine.
Owner:HEBEI MEDICAL UNIVERSITY
New polyglycosides of tripterygium wilfordii with low toxicity, its preparation method and application
ActiveCN106860500BLow toxicityReduce pathological damageAntipyreticDigestive systemTherapeutic effectNephrotic syndrome
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Application of triptophenol terpene in preparation of medicine for treating diabetic nephropathy
The invention discloses an application of triptophenol terpene in preparation of a medicine for treating diabetic nephropathy, belongs to the technical field of medicines, is obtained by separating and purifying tripterygium glycosides extract, and is applied as a single active component or a core component in DKD treatment medicines, and solves the problems that a traditional tripterygium glycosides preparation is high in toxicity and uncontrollable in curative effect. The medicine of the triptophenol terpene can obviously inhibit kidney inflammatory factors (IL-6 and TNF-alpha) and fibrosis markers (TGF-beta); the urine protein level is reduced, and the kidney function is improved; and hepatotoxicity and reproductive toxicity risks are avoided.
Owner:THE FIRST AFFILIATED HOSPITAL OF WANNAN MEDICAL COLLEGE (YIJISHAN HOSPITAL OF WANNAN MEDICAL COLLEGE) +1
Novel composition for treating psoriasis
InactiveCN112641923ALow priceSimple preparation processPeptide/protein ingredientsCarbohydrate active ingredientsInflammatory factorsVitamin C
The invention discloses a novel composition for treating psoriasis. The composition comprises the following components of, in parts by weight, 0.005-0.02 parts of arotinoid ethylester, 1-6 parts of polypeptide, 0.07-0.27 parts of ribose, 15-60 parts of terfenadine, 50-200 parts of vitamin E, 500-2000 parts of aminopeptide, 50-200 parts of aminophylline, 1-10 parts of chlorpheniramine maleate, 100-400 parts of vitamin C, 3-12 parts, 1.5-10 parts of vitamin B2, 10-40 parts of tripterygium glycosides, 4.58-18.33 parts of microcrystalline cellulose, 3.33-13.33 parts of pregelatinized starch, 6.67-26.67 parts of polyvinylpolypyrrolidone and 1-4 parts of talcum powder. The invention provides a method for treating psoriasis by combining traditional Chinese medicines and western medicines. Based on gene regulation and transfer termination of inflammatory factors, cellular immunity and humoral immunity are enhanced at the same time, and the purpose of treating both symptoms and root causes is finally achieved.
Owner:烟台心舒医药科技有限公司
Compound hypoglycemic preparation containing liraglutide and preparation method thereof
InactiveCN106310237ARestore metabolic functionRestore secretory functionPeptide/protein ingredientsMetabolism disorderDuloxetineSide effect
The invention discloses a compound hypoglycemic preparation containing liraglutide and a preparation method thereof. The compound hypoglycemic preparation comprises the following components: liraglutide, Sphallerocarpus Racills polysaccharides, tetrandrine, saccharicterpenin, Spriulina polysacchrides, mixed kinases, potassium magnesium aspartate, fenofibrate, calcium dobesilate, vascular endothelial growth factor, duloxetine, monosialoteterahexosyl ganglioside, tripterygium glycosides, pentoxifylline, and edaravone. The compound hypoglycemic preparation of the invention has a hypoglycemic effect by rectifying metabolic disorder, restoring renal metabolic function, restoring insulin secretion function, promoting regeneration of islet cells, and repairing damaged islet cells; and can resorb and utilize the blood excessive sugar while restoring renal metabolic function. The compound hypoglycemic preparation of the invention is used for eliminating diabetes and the diabetic complications of eyes, kidneys, heart, nerves and limbs, and has the characteristics of distinct therapeutic effect and stable low side effects.
Owner:卢连伟
Compound preparation for reducing hepatotoxicity of tripterygium glycoside tablets, and preparation method of compound preparation
InactiveCN111297814AReduce liver toxicityGood curative effectOrganic active ingredientsAntipyreticEfficacyBiology
The invention discloses a compound preparation for reducing hepatotoxicity of tripterygium glycoside tablets, and a preparation method of the compound preparation. The compound preparation comprises silibin meglumine tablets and the tripterygium glycoside tablets. The compound preparation has the efficacies of protecting the liver for detoxification, tonifying the kidney and strengthening the spleen; the dosage of tripterygium glycosides can be obviously increased; a better curative effect is achieved; and meanwhile, the hepatotoxicity of the tripterygium glycosides is obviously reduced. In addition, according to the compound preparation, the fast release of silibin meglumine and the long-acting stable release of tripterygium glycosides can be realized, and the treatment effect is furtherimproved. In addition, the preparation method provided by the invention has the advantages that the operation is simple; the cost is low; the preparation method is suitable for industrial production;and the application prospects are good.
Owner:HUNAN QIANJIN XIELI PHARMA CO LTD
Preparation of 2r-cardiospermin-5-p-hydroxybenzoate and its application in the preparation of drugs for treating rheumatoid arthritis
ActiveCN106974921BHighlight substantive featuresOrganic active ingredientsSugar derivativesPharmacologyChinese herbology
The invention relates to chemical structure and a preparation method of a compound 2R-cardiospermin-5-p-hydroxybenzoate as well as an application of the compound in preparing medicines for treating rheumatoid arthritis. The 2R-cardiospermin-5-p-hydroxybenzoate, as a novel compound purified and prepared from a conventional traditional Chinese medicine, namely Sorbaria sorbifolia (L.) A. Brown, by the inventor, can be used for obviously inhibiting PEG2 and NO levels in serum of a mouse with adjuvant arthritis, and the compound is close to tripterygium glycosides at an equivalent dosage in activity; therefore, the compound can be used for preparing the medicines for treating and resisting the rheumatoid arthritis. The chemical structure and the preparation method of the compound as well as anti-RA (rheumatoid arthritis) activity of the compound are disclosed for the first time, therefore outstanding substantive features are guaranteed.
Owner:BINZHOU MEDICAL COLLEGE
Pharmaceutical composition for treating autoimmune diseases or kidney diseases and tripterygium glycosides tablets containing pharmaceutical composition
PendingCN120531693ACompound screeningOrganic active ingredientsAutoimmune conditionAutoimmune disease
The invention relates to the technical field of traditional Chinese medicines, in particular to a pharmaceutical composition for treating autoimmune diseases or kidney diseases and tripterygium glycosides tablets containing the pharmaceutical composition. The pharmaceutical composition disclosed by the invention is prepared from five active ingredients, namely triptolide, triptophenolide, neotriptophenolide, triptochloro lactone and triptophenolide. On the basis of cell membrane chromatography (CMC) and mass spectrometry technologies, active ingredients, having a specific binding effect on glomerular podocytes, in the tripterygium glycosides tablets are screened and identified, and the toxicity is reduced and the curative effect is improved by optimizing the formula ratio. In-vitro cell experiments and animal model verification are combined, and a novel tripterygium glycosides tablet formula strategy is provided. Research results show that the optimized composition significantly reduces hepatotoxicity and reproductive toxicity while retaining core anti-inflammatory and anti-fibrosis activity, and provides a safer solution for clinical application of the tripterygium wilfordii preparation.
Owner:THE FIRST AFFILIATED HOSPITAL OF WANNAN MEDICAL COLLEGE (YIJISHAN HOSPITAL OF WANNAN MEDICAL COLLEGE)
Traditional Chinese medicine composition and preparation for treating rheumatoid arthritis and preparing method and application thereof
InactiveCN110464773AGood treatment effectSignificant effectAntipyreticAnalgesicsCurative effectTherapeutic effect
The invention discloses a traditional Chinese medicine composition and preparation for treating rheumatoid arthritis and a preparing method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 80-100 parts of helleborus thibetanus, 20-30 parts of schisandra chinensis, 20-30 parts of ganoderma lucidum, 15-30 parts ofradix aucklandiae, 25-50 parts of vervain, 20-30 parts of radix paeoniae rubra, 30-40 parts of nduoh nyaatv buerng, 50-80 parts of a traditional Chinese medicine named 'Sanheliu' according to the Chinese pronunciation, 20-40 parts of polygonum multiflorum, and 30-60 parts of camphor root. The composition has good therapeutic effect on rheumatoid arthritis, and has the curative effect superior to that of tripterygium glycoside.
Owner:江阴持一堂医药科技有限公司
Tripterygium glycosides tablet and preparation method thereof
The application relates to the field of biological medicine, and discloses a tripterygium glycosides tablet and a preparation method thereof; the preparation method comprises the following operation steps: uniformly mixing tripterygium glycosides, corn starch, pregelatinized starch and low-substitution hydroxypropyl cellulose, adding a binder to mix and granulate, integrating the granules, mixing the granules with magnesium stearate and silicon dioxide, pressing the granules to obtain a tablet core; step 2: (1) spraying a pregelatinized starch aqueous solution on the surface of the tablet core through a bottom-spraying type fluidized bed to form a wet adhesion layer, and then spraying probiotic microcapsules to form a probiotic microcapsule inlaid layer, so as to obtain a probiotic tablet core; (2) spraying a gastric-soluble coating liquid to form a coating layer, and obtaining the tripterygium glycosides tablet.
Owner:JIANGSU MEITONG PHARM CO LTD
A system for determining the individual effectiveness of tripterygium glycosides in the treatment of rheumatoid arthritis by the expression of multiple miRNAs
The invention provides a system for determining the individual effectiveness of treating rheumatoid arthritis by tripterygium glycosides tablets through the expression amount of various miRNAs (microRibonucleic Acid). The various miRNAs comprise hsa-miR-550b-2-5p, hsa-miR-4797-5p, hsa-miR-6509-5p and hsa-miR-378g. The invention further provides a molecular marker for determining the individual effectiveness of treating the rheumatoid arthritis by the tripterygium glycosides tablets, application of the molecular marker to preparation of a kit for determining the individual effectiveness of treating the rheumatoid arthritis by the tripterygium glycosides tablets, and application of a reagent for detecting the expression amount of the molecular marker to the preparation of the kit for determining the individual effectiveness of treating the rheumatoid arthritis by the tripterygium glycosides tablets. The invention provides a high-specificity and high-sensitivity molecular marker and a curative effect predication model for individual diagnosis and treatment of the rheumatoid arthritis.
Owner:INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI
Preparation of sutherlandin-5-cis-p-coumarate and its application in the preparation of drugs for treating rheumatoid arthritis
ActiveCN106974923BHighlight substantive featuresOrganic active ingredientsSugar derivativesPharmacologyMultiglycosidorum tripterygii
The invention relates to a chemical structure and preparing method of the compound sutherlandin-5-cis-p-coumarate and application of the compound to preparation of drugs for treating rheumatoid arthritis. Sutherlandin-5-cis-p-coumarate is a novel compound prepared from the traditional Chinese medicine Sorbaria sorbifolia (L.) A. Brown. through purification by the applicant of the invention. The compound can remarkably suppress the level of PEG2 and NO in serum of adjuvant arthritis rats. The activity of the compound is close to that of tripterygium glycosides of the same dose, and the compound can be used for preparing drugs for treating rheumatoid arthritis. The chemical structure, preparing method and anti-RA activity of the compound are disclosed for the first time, thus having prominent and substantive features.
Owner:BINZHOU MEDICAL COLLEGE
Preparation of sutherlandin-5-p-hydroxybenzoate and its application in the preparation of drugs for treating rheumatoid arthritis
ActiveCN106977561BHighlight substantive featuresSugar derivativesAntipyreticPharmaceutical SubstancesHydroxybenzoate
The present invention relates to the chemical structure and preparation method of a compound Sutherlandin-5-p-hydroxybenzoate, and the application of the compound in the preparation of medicines for treating rheumatoid arthritis. Sutherlandin‑5‑p‑hydroxybenzoate is a new compound purified and prepared by the applicant of the present invention from the traditional Chinese medicine Sorbaria sorbifolia (L.) A. Brown. It can significantly inhibit the PEG in the serum of rats with adjuvant arthritis 2 and NO level, and its activity is stronger than that of tripterygium glycosides in the same dose, and can be used to prepare medicines for treating rheumatoid arthritis. The chemical structure, preparation method and anti-RA activity of the compound are disclosed for the first time, so it has outstanding substantive features.
Owner:BINZHOU MEDICAL COLLEGE
Kit for evaluating effective dosage of tripterygium glycosides for treating diabetic nephropathy
The invention discloses a kit for evaluating the effective use dosage of tripterygium glycosides for treating diabetic nephropathy, and belongs to the technical field of medicine, the kit comprises labeled demethylzeylasteral, an SPE 96 pore plate for serum sample treatment, and a reversed-phase chromatographic column for UPLC-MS (Ultra Performance Liquid Chromatography-Mass Spectrometry) analysis. According to the application, demethylzeylasteral is taken as a pharmacodynamic marker of tripterygium glycosides for treating diabetic nephropathy, so that the problem that the dosage of tripterygium glycosides is not matched with the curative effect and the safety in the treatment of diabetic nephropathy is solved, the treatment scheme can fit the individual condition of a patient, and accurate medication is realized; the effective dose of tripterygium glycosides for treating diabetic nephropathy can be judged, and poor curative effect caused by improper dose can be avoided; severe side effects possibly caused by the medicine are avoided, and the medication risk is reduced especially for patients who use the medicine for a long time.
Owner:BEIJING HOSPITAL +1
Extraction method for tripterygium glycosides
The invention discloses an extraction method for tripterygium glycosides. The method comprises the following steps of: (1) sample pretreatment: cleaning and smashing tripterygium wilfordii Hook. f. roots to obtain a powder sample; (2) crude product extraction: adding the powder sample into 50-60% ethyl alcohol at a solid-liquid ratio of 1:15-25, carrying out ultrasound extraction for 70-100 min under a condition of 200-300 W and 60-75 DEG C, and concentrating an extraction solution to 15-25% of the volume; and (3) crude product purification: adding a concentrate obtained in S (2) into chloroform at a solid-liquid ratio of 1:1-2, carrying out microwave extraction for 90-120 min under a condition of 280-380 W and 60-62 DEG C, and concentrating the extraction solution until specific gravity is 1.2-1.6. According to the method, the use amount of harmful organic solvents can be greatly lowered, an extraction rate of the tripterygium glycosides is obviously improved, the purity of effectiveingredients, including triptolide, triptonide, tripterine and wilforlide A, can be obviously improved, in addition, the extraction method is convenient in an extraction operation and can be easily controlled, and industrial production efficiency is improved.
Owner:HUNAN QIANJIN XIELI PHARMA CO LTD
Preparation of 2s-cardiospermin-5-benzoate and its application in the preparation of drugs for treating rheumatoid arthritis
ActiveCN106977560BHighlight substantive featuresOrganic active ingredientsSugar derivativesPharmaceutical SubstancesPharmacology
Owner:BINZHOU MEDICAL COLLEGE
Dry coating sustained-release tablet for treating arthritis and preparation process thereof
InactiveCN1969929AEasy to takeComplies with the law of toxic releaseOrganic active ingredientsAntipyreticSustained Release TabletControlled Release Tablet
The invention discloses a kind of dry dressed controlled release tablets for treating arthritis which comprises medicinal cores and dry coating sheet, wherein the dry coating sheet comprises slow release matrix material 110-150 parts, hole-making agent 100-120 parts, right amount of binding agent and magnesium stearate. The medicinal cores comprise Tripterygium wilfordii glycosides 20-30 parts, crumbling agent 10-20 parts, bonding agent 20-30 parts, thinning agent 30-40 parts, and right amount of magnesium stearate.
Owner:SOUTHERN MEDICAL UNIVERSITY